Locations:
Search IconSearch

First Trial of DBS for Stroke Rehabilitation: Insights on the Underlying Science (Video)

Investigator speaks to potential applications beyond stroke

DBS

As previously reported on this blog, Cleveland Clinic researchers have launched the first clinical trial to examine the use of deep brain stimulation (DBS) to promote motor function recovery in disabled stroke survivors. The trial, launched in 2016 (a DBS device was implanted in the first patient in December), was awarded nearly $5 million in funding from the NIH’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The trial’s lead investigator, neurosurgeon Andre Machado, MD, PhD, recently shared some insights on the trial’s clinical implications in this video post. Dr. Machado explains the essentials of the trial, which patients are candidates, and how DBS for stroke recovery differs from neuromodulation for movement disorders.

“Our primary hypothesis is that by applying DBS to the connections between the cerebellum and cerebral cortex, we can facilitate the plasticity that occurs in the cortex around the stroke and thereby promote recovery of function beyond what physical therapy alone can do,” Dr. Machado notes. “We need more and better options to help the many patients who remain chronically disabled after a stroke.”

Now co-investigator Kenneth Baker, PhD, assistant staff in Cleveland Clinic’s Department of Neurosciences, speaks to some of the scientific implications of the study’s attempt to stimulate the brain’s dentatothalamocortical pathway to restore lost motor function. He also explains how Cleveland Clinic’s recent NIH BRAIN grant award is supporting the team’s work.

“We know that deep cerebellar stimulation promotes motor recovery in a preclinical model of cortical stroke,” says Dr. Baker. “Our goal is to advance this therapy to promote recovery of motor function in humans. This has the potential to be a significant advancement for the field.”

Check out his insights in the video below.

Advertisement

Related Articles

neuron-affected-by-neuromyelitis-optica

NMOSD: Multiple Monoclonal Antibodies Have Expanded Treatment Options

How to use? Consider starting during the acute attack and seek patient preferences for chronic use

colorful brain scan with a red arrow pointing to a spot on right side
June 4, 2026/Neurosciences/Epilepsy

MR Fingerprinting Sharpens Lesion Detection in Epilepsy Surgery Candidates

Quantitative imaging adds diagnostic value beyond 3T MRI in nearly half of patients

Illustration of spine x-ray with radiating red light indicating pain

Baclofen Pump Management and Malfunction Detection

Expert shares insight on intrathecal baclofen pumps to treat spasticity

Dr. Osama Kashlan against a decorative background with podcast icon overlay
June 2, 2026/Neurosciences/Podcast

Endoscopic Spine Surgery: Current and Emerging Roles (Podcast)

Opportunities and impacts of a growing surgical approach

stylized illustration of a chemical compound made up of connected multicolor spheres

What’s the Outlook for BTK Inhibitors in Progressive Multiple Sclerosis?

Despite safety concerns and mixed trial results, experts see potential for this indication

Illustration of two football helmets butting into each other with an inflamed brain underneath one helmet

A Call to Find and Validate Diagnostic Biomarkers for Chronic Traumatic Encephalopathy

Experts endorse a push to improve prevention and treatment following repetitive head injury

dr. charles bernick against decorative background with podcast icon overlay
May 18, 2026/Neurosciences/Podcast

Recognizing and Managing Alzheimer’s Disease in People With Down Syndrome (Podcast)

A population with very high lifetime risk presents care challenges and pathophysiologic insights

Dr. Dylan Wint talking to a patient in a medical office

Alzheimer’s Disease Nears an Inflection Point in Diagnosis and Care

Two Cleveland Clinic neurologists review biomarker advances, targeted therapies and unresolved clinical challenges

Ad